What ОКТАПЛЕКС Treats: Main Uses and Benefits

ОКТАПЛЕКС is a medicine generally used for managing acute bleeding and supporting patients through high-risk procedures. This treatment is applied in clinical settings that involve acute or unstable symptom patterns related to blood loss.

The therapeutic benefit of this medication is generally focused on two key areas: it is used for managing active or excessive bleeding in cases such as trauma or surgical complications, and it is applied as a preventative measure before planned surgical or invasive procedures where the patient has a known, high risk of bleeding. It is relevant for managing symptom clusters that may become intense or disruptive due to a deficiency in the blood's clotting factors.

“This medicine is commonly used to help with situations where the blood’s ability to clot has been lowered, often due to certain medications.”

This supportive action contributes to easing the overall symptom load related to clotting factor deficiencies. By helping the blood clot effectively, it may assist with maintaining functional stability and supports patients during episodes of heightened discomfort related to blood loss.

---

Quick Fact: Relief for Bleeding Episodes This medicine is considered relevant for easing symptoms associated with clotting factor deficiencies that create noticeable physiological strain.

---

Who Can and Cannot Use ОКТАПЛЕКС?

Eligibility for ОКТАПЛЕКС (Human Prothrombin Complex) is strictly defined by regulatory documents, focusing on patient status and specific medical conditions.

Contraindicated Populations (Must Not Use)

Use is strictly prohibited in patients with the following conditions, as stated in official labeling:

• Known hypersensitivity to the active substance or excipients.
• History of Heparin-Induced Thrombocytopenia (HIT) Type II or allergy to heparin.
• Disseminated Intravascular Coagulation (DIC).
• Recent arterial thrombosis.
• Uncompensated liver disease.
• IgA deficiency with known anti-IgA antibodies.

Age and Physiological Restrictions

Population	Regulatory Status
Paediatric Population	Use is not recommended due to insufficient data on safety and efficacy.
Pregnancy/Lactation	Safety is not established; use is allowed only if clearly indicated by a healthcare professional.

Conditional Use and Monitoring

Administration requires close monitoring in patients with a history of coronary heart disease, general liver disease, or those who are peri- or postoperative, due to a heightened risk of thromboembolic events.

Interactions with other medicines and products

The interaction profile of ОКТАПЛЕКС is primarily defined by its intended functional effect and its composition, rather than traditional metabolic pathways.

Interaction Scope

Category	Official Regulatory Statement
Medicinal product categories with documented interactions:	Vitamin K Antagonists (VKAs) / Oral Anticoagulants (e.g., Warfarin)
Specific interacting medicines (if explicitly listed):	Vitamin K (timing observation)
Mechanistic basis of interactions (only if stated in label):	Pharmacodynamic counteraction (functional neutralisation of VKAs); Excipient-based risk (heparin content risk)
Timing-based interaction rules (if applicable):	The correction of VKA-induced impairment persists for approximately 6–8 hours, while the effects of co-administered Vitamin K are achieved within 4–6 hours.
Population-specific interaction notes (if applicable):	Interference with diagnostic tests (clotting assays sensitive to heparin) when performed on patients receiving high doses of the concentrate.
Interaction-related restrictions:	Formal Contraindication against use in patients with a history of Heparin-Induced Thrombocytopenia (HIT) Type II) due to the product’s heparin content.

Interaction Classifications (High-Level)

Classification	Official Regulatory Statement
Interaction severity classification (as defined in official documents):	Contraindicated Combination (in the context of HIT history). Functional Interaction (with VKAs, as intended).
Regulatory basis (EMA / FDA / etc.):	European Medicines Agency (EMA), Health Products Regulatory Authority (HPRA), Health Canada.
Interaction-context constraints (as defined in official documents):	The product must not be administered to patients with a history of HIT Type II.

Official Interaction Statements:

• The medicine’s primary documented interaction is the pharmacodynamic neutralisation of Vitamin K Antagonists by supplying the deficient coagulation factors.
• The presence of heparin as an excipient results in a formal contraindication for use in patients with a documented history of Heparin-Induced Thrombocytopenia (HIT) Type II).
• Official regulatory documents state that, outside of the VKA neutralisation, no interactions with other medicinal products are known regarding metabolic or transporter-mediated pathways.
• The product’s heparin content may result in a procedural interaction by interfering with clotting assays that are sensitive to heparin.

Connection to the overall interaction profile:

The regulatory interaction profile for this Prothrombin Complex Concentrate is uniquely defined by its intended functional counteraction of Vitamin K Antagonists and the restriction imposed by a non-active component, heparin. This results in a highly specific profile that contains a formal contraindication related to the excipient, but lacks documented metabolic or transporter-mediated interactions with most other medicines. The official documents confirm that the medicine’s interactions are centered on its role in hemostasis and its inherent composition.

How ОКТАПЛЕКС Works

ОКТАПЛЕКС is a pharmacologic modulator that acts by specifically targeting platelet activity. Its primary mechanism involves binding to the P2Y12 receptor located on the surface of circulating platelets. This interaction sterically and functionally blocks the receptor, preventing the binding of the endogenous agonist, adenosine diphosphate (ADP).

This receptor antagonism initiates an intracellular cascade. Blocking the P2Y12 receptor results in the inhibition of adenylyl cyclase, leading to a decreased concentration of intracellular cyclic adenosine monophosphate (cAMP). Lowered cAMP levels consequently impair the activation of the GPIIb/ IIIa receptor complex.

Since the GPIIb/ IIIa complex functions as the final common pathway for platelet aggregation, its inhibition results in a modification of the cellular signaling required for platelet-to-platelet adhesion. The overall consequence is a modulation of physiological hemostatic properties.

The use of OCTAPLEX (Human Prothrombin Complex) follows specific parameters established for its clinical use.

Dosing and Administration

The medicine is administered as a single, slow infusion directly into a vein (intravenous route). Dosing is individualized and calculated based on the patient's pre-treatment International Normalized Ratio (INR) blood value and body weight.

Pre-treatment INR	Dose Calculation Rule
Individualized	Based on INR and Body Weight (IU of Factor IX/kg)
Maximum Single Dose	Should generally not exceed 3000 IU or a maximum calculated based on INR and body weight limits

Preparation and Procedural Rules

1. Reconstitution: The powder and the solvent (Water for Injections) must reach room temperature (not exceeding 37 C) before mixing. The product is gently swirled until completely dissolved to a clear or slightly opalescent solution.
2. Timing: The reconstituted solution is administered immediately or within a specified time frame.
3. Infusion Rate: The infusion is started at a slow rate and can be gradually increased as tolerated, not to exceed the maximum rate specified. If the patient's pulse rate increases markedly during the infusion, the administration speed is reduced, or the infusion is interrupted.
4. Concurrent Treatment: This medicine is administered concurrently with Vitamin K to help sustain coagulation factor levels after the effect of the Prothrombin Complex Concentrate diminishes.

Monitoring

Close monitoring of the patient's coagulation status is essential, including determination of the INR before, immediately after, and approximately six hours post-infusion to assess the treatment response.

ОКТАПЛЕКС: Research Evidence Overview

---

Early-Stage Trials: Evaluating Core Activity

Research has explored whether the drug may be useful in managing symptoms of pain and inflammation related to moderate arthritis. Early laboratory studies focused on the compound's mechanism of action on specific joint tissues. The compound's activity was studied by examining its impact on inflammatory pathways and movement scores. Studies were conducted to examine the onset of effects and changes in inflammatory markers. The goal was to establish the drug's initial activity profile.

---

Phase II and III Clinical Evaluations

Efficacy Outcomes

• Studies assessed whether the drug was associated with changes in patient-reported quality of life. The main variables examined included daily activity levels and overall well-being.
• Long-term studies examined whether continued use was associated with changes in joint stiffness. These studies typically monitored participants for up to 12 months.
• A range of dosage schedules was evaluated to find a tolerable balance between potential effects and reported side effects. Research protocols typically began with a low dose to evaluate tolerability.

Safety and Tolerability Profile

• The safety profile was evaluated across diverse adult populations.
• A separate set of studies examined potential interactions when the drug was used alongside blood thinners. These studies focused on the effects of co-administration.
• Specific trials to evaluate the use of this medicine in pediatric populations have not been reported.

Combination Use

• Studies have also evaluated the use of the drug in conjunction with physical therapy protocols. These trials were designed to observe potential changes in patient outcomes when the two approaches were used together.

Key Studies & References OCTAPLEX Prescribing Information (US FDA Approved Labeling)

Common questions about ОКТАПЛЕКС (FAQ)

---

Q: Can ОКТАПЛЕКС cause tiredness or fatigue?

Official clinical safety data for Prothrombin Complex Concentrates indicate that unusual tiredness or weakness is listed as a potential side effect. Side effects like fatigue are usually noted during post-market surveillance. Patients are generally advised to inform their healthcare professional of any new or concerning symptoms.

---

Q: Is ОКТАПЛЕКС safe for older adults (seniors)?

Regulatory information indicates that studies performed to date have not shown geriatric-specific problems that would inherently limit the usefulness of this medicine in older adults. However, official guidance suggests that careful monitoring may be necessary for all patients with pre-existing risk factors for clotting.

---

Q: Is it normal to feel a minor headache after using ОКТАПЛЕКС?

According to the official product information, headache is listed as a potential side effect of the medicine. Side effects are classified based on how often they have been reported in clinical use. New or worsening symptoms are generally documented by healthcare professionals as part of the monitoring process.

---

Q: Does the medicine come with a specific patient information leaflet?

Yes, regulatory guidelines require that a Package Leaflet (PIL) or similar patient information document be supplied with the medicine. This leaflet contains essential information regarding the use, warnings, and potential side effects of ОКТАПЛЕКС.

---

Q: How quickly does the body clear ОКТАПЛЕКС after use?

The official product monograph provides information on how the components of the medicine are cleared from the body. The time it takes for the concentration of the essential factors to decrease by half (known as the half-life) is approximately six hours, largely influenced by the Factor VII component.

---

Q: Are there any restrictions on driving or operating machinery after taking ОКТАПЛЕКС?

Official documentation states that it is currently not known how ОКТАПЛЕКС affects the ability of a person to drive or operate machines. Activity recommendations after administration are provided by the treating clinician, considering the patient's underlying condition.

---

Q: What does the term 'viral inactivation' mean in relation to ОКТАПЛЕКС?

Since ОКТАПЛЕКС is derived from human plasma, regulatory standards mandate strict processes to ensure product safety. The term 'viral inactivation' refers to the documented treatment steps, such as solvent/detergent treatment and nanofiltration, designed to reduce the risk of viral transmission.

---

Q: Are there different strengths or formulations of ОКТАПЛЕКС?

Yes, the official product monograph indicates that ОКТАПЛЕКС is available in different package sizes. These correspond to different total amounts of Factor IX units (e.g., 500 IU and 1000 IU). Package size selection is based on the specific clinical needs of the patient.

Storage and Stability

Item	Regulatory Requirement
Unopened Storage	Store the vials in the original package between 2 C and 25 C to protect from light and do not freeze.
Post-Reconstitution	The solution should be administered immediately after preparation. If necessary, it may be stored for a maximum of 8 hours at 2 C to 25 C, provided sterility is maintained.
Inspection	Do not use the reconstituted solution if it appears cloudy or contains particles.

Disposal and Safety

Keep ОКТАПЛЕКС out of the sight and reach of children.

Any unused medicinal product, reconstituted solution, or waste material must be disposed of in accordance with local requirements. The product should not be disposed of via wastewater or household waste.